Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4314299 | 0.85 | PTPRC (0.49) | PTPRCPTPN1MRGPRX4F2NR4A2 | |
| Hydrochloric Acid SCHEMBL6334189 | 0.85 | F2 (0.48) | PTPRCPTPN1MRGPRX4F2NR4A2 | |
| Amelubant SCHEMBL1891670 | 0.80 | GRM5 (0.45) | PTPRCPTPN1MRGPRX4F2NR4A2 | |
| Amelubant SCHEMBL29359085 | 0.80 | GRM5 (0.45) | PTPRCPTPN1MRGPRX4F2NR4A2 | |
| SCHEMBL4999957 | 0.78 | F2 (0.72) | F2 | |
| SCHEMBL31506335 | 0.78 | F2 (0.72) | F2 | |
| SCHEMBL6354816 | 0.78 | PTPRC (0.46) | PTPRCPTPN1MRGPRX4F2FFAR1 | |
| Hydrochloric Acid SCHEMBL6557386 | 0.77 | F2 (0.73) | F2 | |
| SCHEMBL668003 | 0.77 | PTPRC (0.46) | PTPRCPTPN1MRGPRX4F2NR4A2 | |
| Hydrochloric Acid SCHEMBL7631983 | 0.76 | F2 (0.46) | PTPRCPTPN1MRGPRX4F2NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682086-A2 | PHARMACEUTICAL FORMULATION CONTAINING AN LTB4 ANTAGONIST, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF | Boehringer Ingelheim International GmbH (DE) | 2006-07-26 | — | — | EP | claimed |
| US-20050129768-A1 | Pharmaceutical formulation containing an LTB4-antagonist, as well as processes for the preparation thereof and the use thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-16 | — | — | US | claimed |
| WO-2005041855-A2 | PHARMACEUTICAL FORMULATION CONTAINING AN LTB4 ANTAGONIST, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-12 | — | — | WO | claimed |
| EP-1818047-A2 | Oral administration form for difficulty soluble basic active ingredients | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-08-15 | — | — | EP | disclosed |
| US-20050129768-A1 | Pharmaceutical formulation containing an LTB4-antagonist, as well as processes for the preparation thereof and the use thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-16 | — | — | US | disclosed |
| US-20050095293-A1 | Administration form for the oral application of poorly soluble drugs | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2005-05-05 | — | — | US | disclosed |
| EP-1499298-A1 | ORAL ADMINISTRATION FORM FOR DIFFICULTY SOLUBLE BASIC ACTIVE INGREDIENTS WHICH ARE APPLIED ORALLY | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003074032-A1 | ORAL ADMINISTRATION FORM FOR DIFFICULTY SOLUBLE BASIC ACTIVE INGREDIENTS WHICH ARE APPLIED ORALLY | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050129768-A1 | Pharmaceutical formulation containing an LTB4-antagonist, as well as processes for the preparation thereof and the use thereof | LTB4R, LTB4R2, LTA4H | PTPRC 3233/4885PTPN1 1940/4885MRGPRX4 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.